Europe PMCopen access
Assessment of clinical and neuroimaging efficacy of treatment targeting tau pathology in mild cognitive impairment and mild to moderate Alzheimer’s disease with hydromethylthionine mesylate using external control data✰✰✰
Alzheimer’s disease, Tau Aggregation Inhibitor, Hydromethylthionine Mesylate, Critical Path For Alzheimer’s Disease (Cpad)
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 123242
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.